[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].
Aspirin is considered the gold standard antiplatelet therapy for primary and secondary prevention of cardiovascular (CV) disease. However, it appears less protective in diabetic patients than in the general population. This difference is attributed to a higher level of aspirin resistance observed in these subjects when in vitro tests are performed. The frequency of this problem, its mechanistic aspects and its clinical relevance remain largely unknown. Our analysis of the literature confirms a higher proportion of platelets resistant to aspirin in diabetic than in control individuals. This observation deserves further research because it may be associated with an increased risk of CV events and worse prognosis.
Legrand
D A
DA
Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Sart Tilman, Liège, Belgique.
Scheen
A J
AJ
D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D018890:Chemoprevention; D048909:Diabetes Complications / Q000517:prevention & control*; D004351:Drug Resistance; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011322:Primary Prevention; D011379:Prognosis; D020011:Protective Agents / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D020011:Protective Agents; D001241:Aspirin